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a  b  s  t  r  a  c  t
Aim: To report our initial results on the use of radiosurgery for treatment of liver metastases.
Background: In recent years there has been increasing interest in the use of stereotactic body
radiation therapy to treat metastatic disease to the liver as an alternative to interventional
procedures.
Materials and methods: Between November 2008 and June 2015 a total of 36 LINAC-based
radiosurgeries using VMAT were performed in 27 patients with liver metastases from 10
different primary sites. Doses ranged from 21 Gy to 60 Gy in 1 to 5 fractions. In all patients
the  volume of liver receiving less than 15 Gy was more than 700 cc. The volume treated with
the  prescription dose ranged from 1 cc to 407 cc with a median of 58 cc. All patients but one
received systemic treatment.
Results: Overall median survival for the entire group is 9 months (ranging from 1 to 67
months). Local recurrence free survival ranged from 4 to 67 months with a median of 14
months.
Twenty patients (80%) survived more than six months. Three patients treated for
oligometastases were alive after 3 years. Grade 0 toxicity was encountered in 22/27 patients,
Grade 1 toxicity in 5/27 and only 1/27 patient experienced Grade 2 toxicity. No patient
experienced grade 3–4 toxicity.Conclusion: Based on these initial results we conclude that SBRT for treating liver metastaseswith radiosurgery is safe a
tissue  constraints for live
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sites with 7, 5 and 5 patients, respectively (Table 1). Six patients
were oligometastatic, defined as patients who  presented withreports of practical oncology and 
.  Background
any  patients with advanced cancer present with liver
etastases resulting in substantial morbidity and mortality.
hemotherapy is a standard palliative treatment for most
f them, often providing transient responses and increased
verall survival. In selected oligometastatic patients, local
reatment can lead to long disease-free intervals and even per-
anent disease control. Surgery remains the gold standard
or early metastatic focal disease. However, most patients
ill not be surgical candidates. For these patients, alterna-
ive targeted therapies have been developed. One of these,
tereotactic body radiotherapy (SBRT), presents an attractive
on-invasive option for selected patients with limited hepatic
nvolvement.1
SBRT is a form of highly precise radiotherapy using high
ose of radiation in 5 fractions or less, (extreme hypofraction-
tion) with steep dose distributions tightly covering the tumor,
ith rapid dose fall off that requires reproducible immobiliza-
ion, accounting for tumor motion during treatment planning
nd delivery.2
The liver is a common site for metastases, especially from
arcinomas of the colon, lung and breast.3 Liver is the only
ite of metastatic disease in patients with colorectal cancer in
s many  as 40% of patients. Fifteen to twenty-five per cent of
atients present with liver metastases at the time of diagno-
is and this synchronous disease carries the worst prognosis.
t is estimated that as many  as 55% of patients develop liver
etastases during the course of their illness.4Metastatic spread to the liver is a frequent event in a nat-
ral course of many  common solid tumors.5–7 Primary tumor
ig. 1 – 72-Year old female with liver metastases from NSCLC. (a)
lanning treatment using MRI  fusion. Dose: integrated boost (12 G
ractions. (b) PEC CT at diagnosis and consequently follow-up at 
ompletion, respectively, showing complete response.therapy 2 2 ( 2 0 1 7 ) 118–125 119
site, histology, extent of liver metastases and the presence of
metastatic spread profoundly affect the prognosis.
Stereotactic radiotherapy delivered either as a single
fraction or hypofractionated treatment has emerged as a
promising alternative to surgical or interventional options in
metastatic disease to the liver.8–13 A treatment scheme focus-
ing on an effective focal radiation is indicated in early phases
of disease and after proper patient selection. It can also be
used successfully in palliative cases, especially with other
metastatic sites present combined with systemic treatment.14
2.  Aim
The purpose of this study is to report our initial results on
the use of linear accelerator-based radiosurgery as a feasible
alternative for the treatment of liver metastases in patients
that refuse or are not candidates for surgery.
3.  Material  and  methods
From November 2008 to July 2015, twenty-seven patients with
liver metastases were treated with SBRT at one single institu-
tion (Figs. 1–3). There were 12 males and 15 females with ages
ranging from 42 to 83 years old with a median of 67 and a mean
of 66 years. Tumors originated from 10 primary sites. Lung,
breast and colorectal cancer were the most common primary Diagnostic abdomen MRI  and dose in color wash in
y in the periphery and 15 Gy in the center of the lesion) × 3
3 months, and 5 years and 11 months after SBRT
5 or fewer metastases at any site and with a Karnofsky status
(KPS) higher than 70.15,16
d rad120  reports of practical oncology an
3.1.  Selection  criteria
Selection criteria used were based on tumor location, volume,
number of tumors, extent of disease, and general status of the
patient. Patients were not surgical candidates due to comor-
bidities and/or patient refusal to surgery. Criteria for exclusion
were active hepatitis or liver failure (encephalopathy, portal
hypertension, varices) and presence of clinical ascites.
Treatment intent was curative or palliative including the
following:1. Patients with no evidence of extrahepatic disease with local
control of primary tumor or primary tumor potentially con-
trollable.
Fig. 2 – 62-Year old female with liver metastases from melanom
Volumetric image of the liver showing two lesions (in red) treate
treated using a second radiosurgery procedure. (c) First SBRT pla
fractions). (d) Second single fraction SBRT planning treatment (25
showing volume of liver receiving less than 15 Gy. (f) PEC CT follo
therapy. Lesions decreased in size and demonstrated no significiotherapy 2 2 ( 2 0 1 7 ) 118–125
2. Patients with stable disease.
3. Locally progressive liver disease.
4. Progression of disease after chemotherapy or other previ-
ous treatment.
5. Patients with progressive extrahepatic disease.
6. Poor prognosis of the patients due to the presence of one
or more  liver lesions.
7. Karnofsky performance status (KPS) higher than 70.
8. Sufficient liver volume free of disease to comply with tol-
erance (more than 700 cc receiving less than 15 Gy).For pretreatment assessment, all patients underwent
a complete physical examination, liver function tests, CT
and magnetic resonance imaging (MRI) of the abdomen
a. (a) Diagnosis CT abdomen showing three lesions. (b)
d as a cluster with a single isocenter. Green lesion was
nning treatment with dose in color wash (15 Gy × 4
 Gy). (e) Dose volume histogram for the composite plan
w-up 5 months after SBRT: excellent response to the
ant FDG uptake.







Fig. 2 – 
ith intravenous (IV) contrast enhancement unless
ontraindications were present, as well as whole body
ET-CT.Preplanning and planning steps used to ensure consis-
ent patient position reproducibility included the following
teps.
Table 1 – SBRT for liver metastases: a single institution experie
Primary tumor Procedures/n n alive OS (median)
Colon 5/5 1 22 (2–38) 
Breast 6/5 2 (1LFU)a 22 (17–38) 
Lung 12/7 1 9 (1–67) 
Endometrium 1/1 0 6 
Pancreas 2/2 0 8 (6–9) 
Prostate 2/1 0 10 
Gallbladder 1/1 1 24 
Melanoma 4/2 1 (1LFU)a 5 
Ovary 2/2 1 7 (6–8) 
Stomach 1/1 1 3 
Total 36/27 8 9 (1–67) 
a LFU: Lost to follow-up.tinued)
3.2.  Pre-treatment
3.2.1.  Patient  positioning  and  CT  simulation
Abdominal compression to limit diaphragm and intra-fraction
intraabdominal organ motion was used for all patients with
either compression belt or body thermoplastic masks. In some
nce.
 Age (median) Toxicity (acute/late) Oligomets
74 (42–78) G0 1
70 (61–72) Nausea G1Abd pain G1 2
69 (50–83) Nausea G1 2
63 G0 0
62 (62–76) Ascitis G2 0
73 G0 0
82 G0 1
56 (63–49) Nausea G1 0
54 (43–65) G0 0
75 G0 0
67 (42–83) 6
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Fig. 3 – 64-Year old male with liver metastases from gastric carcinoma. (a) Volumetric image showing the location of 5 liver
metastases. (b) Axial, coronal and sagittal views of the isodose distribution in the treatment planning for treating the 5
 doslesions with single isocenter. Dose: 15 Gy × 3 fractions. Total
patients with smaller tumors, CT images from normal respi-
ration, non-extreme exhalation and inhalation were acquired
to obtain the internal target volume (ITV) using 1 or 2 mm
slices for smaller lesions and up to 2.5 mm for larger lesions.
Three phase IV contrast enhanced CT was obtained unless
contraindicated.
3.2.2.  Treatment  planning
Gross tumor volume (GTV) was contoured using planning CT
(normal respiration) registered with either MRI or PET-CT diag-
nostic image.  ITV was obtained using images in three respi-
ratory phases. Planning target volume (PTV) margins were
usually set at 3–5 mm from ITV depending on the size and loca-
tion of the lesion as well as per physician discretion. Dose was
prescribed depending on the size and location of the lesion
with all plans complying with liver tolerance criteria having at
least 700 cc of normal liver receiving a dose lower than 15 Gy.
3.2.3.  Treatment  delivery
Image  guided radiation therapy (IGRT) using cone beam CT
(CBCT) was used for every fraction. In selected cases we
used oral contrast during each treatment fraction to localize
the duodenum. Treatment was delivered in 1–5 fractions
with doses ranging from 5–20 Gy per fraction. From two to
up to 7 coplanar/non coplanar arcs with VMAT Technique
(volumetric modulated arc therapy) were used. The most
common regimen consisted of 3 fractions of 12 Gy to 20 Gy
per fraction. Treatments were not given on consecutive days.e: 45 Gy.
Usually two to three fractions per week were delivered and
the mean number of elapsed days ranged from 7 to 14. The
beam on time ranged from 2 to 9 minutes with a median of 4
and 4 minutes as average.
3.2.4.  Follow-up
Every patient was closely followed to evaluate treatment
tolerance and acute toxicity during the treatment. First
follow-up was at 3 months after completion of treatment. The
following ones were each within a 6 months period. Patients
were assessed clinically and with serial liver functional tests
(LFT) to evaluate late toxicity. Acute and late toxicity was
scored according to the Common Terminology Criteria for
Adverse Events v4.0 (CTCAE v 4.00). Local failure (LC) was
defined by imaging according to the Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1. Extrahepatic tumor
status was classified as either no evidence of disease (NED),
stable (SD) or progressive disease (PD). Contrast enhanced CT
scans, MRI and/or PET-CT images were used to evaluate the
response to treatment.
Besides basic descriptive statistics, Kaplan–Meier statistics
was used for survival analysis.4.  Results
Of the 27 patients treated, two were lost on follow-up. Eight
of 25 patients (32%) are alive with a median follow-up of 6
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Table 2 – Local control vs dose delivery, tumor size and oligometastatic status.
Liver status Number of patients Dose Tumor size Oligometastatic
LC 12 [30–60] 41 Gy [13–133] 52 cc 4 O–8 N
SD 6 [21–60] 34 Gy [35–271] 97 cc 1 O–7 N
PD 7 [24–36] 27 Gy [20–405] 153 cc 1 O–6 N
LC, local control; SD, stable disease; PD, progressive disease.
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cbl oFig. 4 – Patient overall survival.
onths ranging from 1 to 67 months. Patient overall sur-
ival is shown in Fig. 4. Overall median survival after SBRT
or the entire group was 9 months (Table 1). Twelve patients
ad local control (Table 2), eight with progression of extra-
epatic disease and four with no evidence of disease. Local
rogression-free survival (Fig. 5) ranged from 4 to 67 months
ith a median of 14 months. For this subgroup of twelve
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Fig. 5 – Local progression-free survival.Fig. 6 – Survival analysis comparison for patient with colon,
breast and lung primary (blue) vs other primaries (green).
with a median of 41 Gy and an average of 43 Gy. The minimum
and maximum target volumes were 13 cc and 133 cc with a
median of 52 cc. Seven patients had local progression. All of
them were treated with total dose between 24 Gy and 36 Gy
with a median of 27.5 Gy. The minimum and maximum tar-
get volumes were 20 cc and 405 cc with a median of 153 cc and
average 152 cc. The remainder six patients had stable disease
in the liver.
Best survival was achieved in patients with colon, breast
and lung primaries (Fig. 6) with median overall survivals of 22,
20 and 9 months, respectively (Table 1). Twenty patients (80%)
survived more  than six months, ranging from 8 to 67 months
with a median of 18 months. Lung, breast, and colorectal can-
cer were the most common primary sites in this group with
5, 4, and 4 patients, respectively. Ten patients (40%) survived
more than 20 months; six of them had oligometastatic disease
(2 lung, 2 breast, 1 colon and 1 gallbladder cancer primaries).
Three patients (12%) were alive after 3 years. All of them had
oligometastatic disease (1 lung, 1 colon, 1 breast). The volumes
treated on these three patients were 35 cc, 67 cc and 75 cc,
respectively. Survival analysis comparison for oligometastatic
patients vs non-oligometastatic patients is shown in Fig. 7.
One patient with stage IV lung cancer survived 67 months
after the first SBRT procedure to the liver and 8 years after
being treated to her primary lung cancer (Fig. 1).
Grade 0 toxicity was encountered in 22/27 patients, Grade
1 toxicity in 5/27 and only 1/27 patient experienced Grade 2
toxicity (ascites G2 resolved with paracentesis). No patients
experienced grade 3–4 toxicity (Table 3).
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Fig. 7 – Survival distribution function of oligometastatic (Y
green) vs non-oligometastatic (N blue) patients.
Table 3 – SBRT for liver metastases: toxicity grading.
Toxicity/grade G1 G2 G3 G4
Abdominal pain 2 – – –
Nausea 2 – – –
Ascite 1 1 – –
r
Others – – – –
Total (%) 5 (18%) 1 (3%) 0 0
Beam on time per fraction ranged from 2 to 9 min  with a
median of 4 min.
5.  Discussion
In selected patients with liver metastases from colorectal can-
cer consistent with oligometastatic disease such as solitary
liver lesions, 5 year survivals in the order of 50% have been
reported in highly selected patients.17 In more  advanced pal-
liative cases with other metastatic sites present but stable on
effective systemic treatment, with so-called oligoprogression,
local control of active liver metastases may be necessary.18
In these patients who  commonly are not surgical candidates,
other potentially curative or palliative alternate less invasive
but interventional approaches, including thermal or LASER
ablation and chemoembolization, have been utilized. Recently
SBRT has become an attractive option for the management of
unresectable liver metastases.19
In our institution we started using SBRT for liver metas-
tases in 2008 and most of our patients had rather large or
multiple lesions and were not surgical candidates but were
in good general condition (Figs. 1–3). The best results were
found in patients with oligometastatic disease, with 6 of them
surviving after 20 months, and 3 being alive after 3 years.
The comparison between the survival distribution functions
for oligometastatic and non-oligometastatic patients shows a
significant difference with p = 0.002.
A recent experience with SBRT in a rather similar group
of patients with heterogeneous primary tumors, and lesioniotherapy 2 2 ( 2 0 1 7 ) 118–125
characteristics reflecting a more  “real-life” scenario than in
many  prospective studies was reported by Habermhel et al.
with 12- and 18-months local PFS rates of 70% and 59%.20 Our
survival results are not as good (local PFS 28% at 20 months)
perhaps because of a large percentage of patients (64%) with
unfavorable histology (Table 1). In addition, a total dose of less
than 36 Gy, used in 12 patients (44%) appears to be related
with local failure in our group. Target volume could be another
factor influencing results as we see a significant difference
between the median and average target volumes (52 cc vs 97 cc
vs 153 cc) in the group of patients with local control versus
the group of patients that had stable disease and local failure,
respectively.
As expected, patients with oligometastatic disease and
smaller tumor burden had significantly longer survival.
Although our number of cases is too small for optimal sta-
tistical analysis, they tend to confirm previously published
data regarding better survival for patients with liver metas-
tases from primary breast and colorectal cancers.
The low toxicity we  encountered is likely related to our
strict adherence to the previously described protocol to pre-
serve liver function requiring that at least 700 ml  of uninvolved
liver receive less than 15 Gy in 1–5 fractions. Based on our
results, SBRT for treating liver metastases is safe and effective
as long as normal tissue constraints for liver are respected
(Fig. 2e). Even treating large volumes and multiple lesions
mostly in elderly patients, we did not find significant toxicity
suggesting that we  should not refrain from treating patients
who may achieve palliation with a short course of SBRT. This
may avoid costly and/or prolonged chemotherapy regimens or
other traditional alternatives that may have significant toxic-
ity with lower quality of life.21,22
6.  Conclusions
Based on these initial results we  conclude that SBRT for treat-
ing liver metastases with radiosurgery is safe and effective
for treating one or multiple lesions as long as normal tissue
constraints for liver are respected. SBRT for liver metastases
can be used in a variety of patients. Dose regimes can vary
depending on the intent of the procedure. Better results may
be obtained if ablative prescription doses are achieved. How-
ever, for symptomatic control lower doses could be advised in
order to avoid significant toxicity.
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